top of page

Our Science

We are harnessing innovations in multi-omic drug screening and cancer nanotechnology to develop a new class of synthetic lethality cancer therapeutics. 


Kinome Profile Mapping


Transcriptomic RNA seq

Drug Screening

Micellar Nanocomplex

Drug Delivery Platform

Developing Transformative
Therapies for the Deadliest Cancers

Celestra Life Science is a preclinical-stage biotech startup formed by oncology leaders in academia and industry. We are committed to developing innovative medicines for the deadliest cancers.

Synthetic Lethality in RAS-activated Cancers

Our flagship drug CEL100 is a multi-kinase inhibitor that blocks key kinase effectors in all three major oncogenic pathways activated by RAS (RAF-MEK, PI3K-AKT, RalB-TBK1). CEL100 demonstrates robust single-agent activity in RAS-activated cancers across a wide diversity of tumor types and RAS alterations.


Pancreatic Ductal Adenocarcinoma


Urinary Bladder Carcinoma


Castration-Resistant Prostate Carcinoma

Our Team

IMG_3636 headshot.jpg
Co-Founder, Chief Executive Officer
David Lu
MD-PhD Candidate,
Stanford School of Medicine
BSc Molecular Biophysics & Biochemistry,
Yale University
Co-Founder, Chief Medical Officer
Ray Lee, MD, PhD
Former Senior Director of Oncology,
Hoffman-La Roche
Former Director of Clinical Research,
2022.05.02 Evie Cai - Headshot.JPG
Scientific Advisor​
Mark Lemmon, PhD
Yale Cancer Biology Institute
Chair of Pharmacology,
Yale School of Medicine
Chief Operating Officer​
Evie Cai, MPH
Consulting Analyst,
Deloitte Consulting LLC
BA Economics, Yale University
MPH Health Policy, Yale School of Public Health
bottom of page